Simoa® Ultra-sensitive Biomarker Detection
In Dried Blood and Plasma Spots for Alzheimer’s Disease
App Note
Blood-based biomarkers have transformed Alzheimer’s disease (AD) diagnostics, offering minimally invasive and cost-effective solutions. However, traditional AD blood testing presents logistical challenges, including the need for venous blood draws, specialized lab infrastructure, and temperature-controlled transport. Read this app note to learn how Simoa® technology is paving the way for next-generation biomarker research.
Fill out the form to download the App Note